GlaxoSmithKline announced that the FDA has approved Flonase Allergy Relief (fluticasone propionate 50mcg spray) as a once-daily over-the-counter (OTC) treatment indicated for symptoms of seasonal and perennial allergic and nonallergic rhinitis in patients ≥4 years of age. Flonase Allergy Relief contains the same active ingredient and the same dosage strength as prescription Flonase (also from GlaxoSmithKline).
Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. The precise mechanism of action of fluticasone propionate is not known, but corticosteroids have been shown to have a wide range of effects on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation.
Flonase Allergy Relief will be available OTC in early 2015.
For more information visit GSK.com.